A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.

e20580Background: For residual or metastatic thymomas, the majority of patients require second-line therapy after platinum-combination chemotherapy with response rates ranging from 0 to 20%. Prior ...